Why Now & Why PSI?
The resurgence in psychedelic medicine and science over the last 3 decades is disrupting the fields of mental health and neuroscience with multiple clinical trials of psychedelic-assisted therapy showing promise for a wide spectrum of mental health and neuroscience conditions.
However, the recent FDA rejection of MDMA-assisted therapy for PTSD shows that major challenges remain in bringing psychedelic medicines to approval for clinical use.
There is a critical need for expert teams of clinician scientists and mental health care providers experienced in safely delivering psychedelic-assisted therapy in the rigors of modern-day clinical trial management with controlled substances.
The PSI team is a unique multispecialty group of mental health, psychotherapy and neuroscience experts formed by the merging of the PNI TRIP Center and CCPT, who over the last 6 years have collectively conducted multiple clinical trials of psychedelic medicines for conditions such as depression, anxiety, alcohol use disorder, and PTSD and conducted over 2000 ketamine-assisted therapy sessions.
With the launch of PSI in Q2 2025, their two clinics in Santa Monica and Hollywood will be conducting industry-sponsored and investigator-initiated clinical trials of psychedelic medicines and providing ketamine-assisted psychotherapy.
Through the nonprofit Psychedelic Innovation Fund, PSI will also promote education and training in psychedelic science and medicine, and help create an affordable, sustainable and scalable paradigm-shifting model of mental health care.
Next Steps
Our goals
Conduct clinical trials of existing and novel psychedelic medicines for mental health disorders such as major depression, treatment resistant depression, postpartum depression, generalized anxiety disorder, substance use disorders, PTSD and related conditions.
Conduct clinical trials of existing and novel psychedelic medicines for chronic and degenerative neurological conditions such as stroke, TBI, mild cognitive impairment, dementia and pain syndromes.
Provide mental health services including ketamine-assisted psychotherapy and other established psychotherapy services.
Provide education and training in the rapidly evolving fields of psychedelic medicine and science.
Help expand access of psychedelic-based mental health care services to underserved populations.
Years 1 - 3
The primary PSI revenue streams will be from industry-sponsored clinical trials of psychedelic compounds.
The secondary revenue stream will be from ketamine-assisted psychotherapy and other standard psychotherapy services (both insurance covered and cash-pay).
Eventual revenue streams will be from the use of psychedelic medicines in psychedelic-assisted therapy (PAT) as they become FDA-approved or legalized in California.
Act Now
We are seeking to collaborate with like-minded individuals, foundations and family offices who have a strong belief and interest in advancing psychedelic medicines. Our shared goal is for the betterment of humanity and for specifically impacting mental health and neuroscience conditions for which current treatments are often ineffective.
You can support PSI with charitable donations, private foundation grants and Donor-Advised Funds through the nonprofit Psychedelic Innovation Fund (PIF). The mission of PIF is to advance the evidence-based use of psychedelic medicines and psychedelic-assisted therapy for mental health and neuroscience disorders.
To learn more about supporting PSI through the Psychedelic Innovation Fund, please contact Greg Kearns gkearns@psychedelicsci.com or Daniel Kelly dkelly@psychedelicsci.com.
